ReviewZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2026
[Recent advances in the management of iron deficiency and iron deficiency anemia during pregnancy].
Review in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Iron deficiency (ID) and iron deficiency anemia (IDA) are common obstetric complications associated with various adverse pregnancy outcomes. According to the latest evidence-based medical evidence, this article reviews the management strategies for ID and IDA during pregnancy. Intravenous iron therapy provides substantial advantages for patients who cannot tolerate or do not respond to oral iron, as well as for those with severe IDA requiring rapid correction. The application of new-generation intravenous iron agents has improved treatment efficiency; however, their safety in the first trimester warrants further evaluation. Further, monitoring for adverse events, including hypophosphatemia, is necessary. This review further examines the differential diagnosis and management of intravenous iron-related hypersensitivity reactions and complement activation-related pseudoallergy. Management should be individualized based on patient-specific factors in clinical practice, with adherence to evidence-based guidelines to optimize maternal and infant outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.